Bayer HealthCare has received approval for riociguat under the name Adempas for the treatment of adults with inoperable chronic-thromboembolic pulmonary hypertension (CTEPH) or persistent or recurrent CTEPH after surgical treatment by the Ministry of Health, Labour and Welfare (MHLW) in Japan. The MHLW granted an orphan drug designation for riociguat in the CTEPH indication in September 2011....
Bayer recibe aprobación para el Riociguat en Japón para el tratamiento de la crónica-hipertensión pulmonar tromboembólica Información completa en:
http://www.cnmv.es/portal/hr/HRAlDia.aspx?lang=es .